Vivek Ramaswamy - Roivant Sciences Founder Chairman
| ROIV Stock | USD 11.13 0.02 0.18% |
Insider
Vivek Ramaswamy is Founder Chairman of Roivant Sciences
| Age | 39 |
| Phone | 44 20 7400 3347 |
| Web | https://roivant.com |
Vivek Ramaswamy Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vivek Ramaswamy against Roivant Sciences stock is an integral part of due diligence when investing in Roivant Sciences. Vivek Ramaswamy insider activity provides valuable insight into whether Roivant Sciences is net buyers or sellers over its current business cycle. Note, Roivant Sciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Roivant Sciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vivek Ramaswamy six days ago Acquisition by Vivek Ramaswamy of 13357857 shares of Roivant Sciences subject to Rule 16b-3 | ||
Vivek Ramaswamy over six months ago Disposition of tradable shares by Vivek Ramaswamy of Roivant Sciences subject to Rule 16b-3 | ||
Vivek Ramaswamy over six months ago Disposition of 3000000 shares by Vivek Ramaswamy of Roivant Sciences at 11.05 subject to Rule 16b-3 | ||
Vivek Ramaswamy over a year ago Acquisition or disposition of Roivant Sciences securities by Vivek Ramaswamy |
Roivant Sciences Management Efficiency
The company has return on total asset (ROA) of (0.1844) % which means that it has lost $0.1844 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 1.2896 %, meaning that it created $1.2896 on every $100 dollars invested by stockholders. Roivant Sciences' management efficiency ratios could be used to measure how well Roivant Sciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Jens Okkels | Ascendis Pharma AS | 63 | |
| Tom Harris | Phathom Pharmaceuticals | N/A | |
| Rob Henderson | Viridian Therapeutics | N/A | |
| Hal MD | Pliant Therapeutics | N/A | |
| Alexis AM | Blueprint Medicines Corp | 53 | |
| David Socks | Phathom Pharmaceuticals | 50 | |
| Michael LLM | Ascendis Pharma AS | 54 | |
| Birgitte MD | Ascendis Pharma AS | 62 | |
| MBA MD | Pliant Therapeutics | 56 | |
| Henric Bjarke | Inozyme Pharma | 57 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| MS MBA | Inozyme Pharma | 48 | |
| MPH MD | Phathom Pharmaceuticals | 66 | |
| Jack Anders | Revolution Medicines | 49 | |
| Peter BSc | Syndax Pharmaceuticals | 56 | |
| Vahe Bedian | Viridian Therapeutics | N/A | |
| Marvin Caruthers | Viridian Therapeutics | 85 | |
| Anthony Guzzo | Phathom Pharmaceuticals | 51 | |
| Michael Downes | Syndax Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.18 |
Roivant Sciences Leadership Team
Elected by the shareholders, the Roivant Sciences' board of directors comprises two types of representatives: Roivant Sciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roivant. The board's role is to monitor Roivant Sciences' management team and ensure that shareholders' interests are well served. Roivant Sciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roivant Sciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy Mahery, Chief Officer | ||
| Matthew Gline, CEO Director | ||
| Marianne Romeo, Head Management | ||
| Huafeng Xu, Chief Officer | ||
| Josh Chen, General Counsel | ||
| Matt Maisak, Chief Platforms | ||
| Vivek Ramaswamy, Founder Chairman | ||
| Alex Gasner, Executive Health | ||
| Jo Chen, General Counsel | ||
| PharmD MD, President COO | ||
| Drew Kramer, Chief Officer | ||
| Kelly Graff, Head People | ||
| Richard Pulik, Chief Officer | ||
| Deya MD, Chief OfficerInResidence | ||
| Srini Ramanathan, Chief Officer | ||
| Rakhi Kumar, Chief Officer | ||
| Josh JD, General Counsel | ||
| Mayukh MD, Chief President | ||
| David MD, Chief Dermavant |
Roivant Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Roivant Sciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 1.29 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 37.25 % | ||||
| Operating Margin | (74.46) % | ||||
| Current Valuation | 2.78 B | ||||
| Shares Outstanding | 727.95 M | ||||
| Shares Owned By Insiders | 28.91 % | ||||
| Shares Owned By Institutions | 79.52 % | ||||
| Number Of Shares Shorted | 44.88 M | ||||
| Price To Book | 1.58 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Roivant Stock Analysis
When running Roivant Sciences' price analysis, check to measure Roivant Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roivant Sciences is operating at the current time. Most of Roivant Sciences' value examination focuses on studying past and present price action to predict the probability of Roivant Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roivant Sciences' price. Additionally, you may evaluate how the addition of Roivant Sciences to your portfolios can decrease your overall portfolio volatility.